title: Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance.
abstract: OBJECTIVE
  Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline.
  
  
  METHODS
  Patients with prostate cancer who were initially treated by hormone therapy were registered through the J-CaP registration system. This report summarizes the background factors.
  
  
  RESULTS
  From January 2001 to October 2003, 17,872 patients were registered from 395 institutes throughout Japan. The background factors of 17,312 patients were analyzed. The 17,872 patients were estimated as composing more than half of newly diagnosed prostate cancer patients in Japan. Of these, 22.9, 35.1, 32.9 and 8.6% belonged to T1, T2, T3 and T4, respectively. For the purposes of hormone therapy, 77.5% was primary hormone therapy. Neoadjuvant setting and adjuvant setting were 18.1 and 4.3%, respectively. About 60% of the hormone therapy was combined hormone therapy with LH-RHa plus anti-androgens.
  
  
  CONCLUSIONS
  Irrespective of patients' age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy. It is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners.
authors.affiliation: Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan. akazah@md.tsukuba.ac.jp
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
authors.forename: Michiyuki
authors.initials: M
authors.lastname: Usami
authors.forename: Shiro
authors.initials: S
authors.lastname: Hinotsu
authors.forename: Osamu
authors.initials: O
authors.lastname: Ogawa
authors.forename: Susumu
authors.initials: S
authors.lastname: Kagawa
authors.forename: Tadaichi
authors.initials: T
authors.lastname: Kitamura
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Seiji
authors.initials: S
authors.lastname: Naito
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hirao
authors.forename: Masaru
authors.initials: M
authors.lastname: Murai
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D008297:Male; D008495:Medical Oncology / Q000639:trends; D008875:Middle Aged; D009919:Orchiectomy / Q000706:statistics & numerical data; D011471:Prostatic Neoplasms / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone